Cover Image
市場調查報告書

Valeant Pharmaceuticals International, Inc. - 產品平台分析

Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224562
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
Valeant Pharmaceuticals International, Inc. - 產品平台分析 Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016
出版日期: 2016年08月10日 內容資訊: 英文 90 Pages
簡介

Valeant Pharmaceuticals International, Inc.身為一個高度專業性的製藥公司,不只開發製造特殊藥品,更開發製造成藥、學名藥等大範圍醫藥品,其產品銷售世界各地。

本報告提供Valeant Pharmaceuticals International, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Valeant Pharmaceuticals International, Inc.的基本資料

Valeant Pharmaceuticals International, Inc.概要

  • 主要資訊
  • 企業資料

Valeant Pharmaceuticals International, Inc.:R&D概要

  • 主要的治療範圍

Valeant Pharmaceuticals International, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Valeant Pharmaceuticals International, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

Valeant Pharmaceuticals International, Inc.:藥物簡介

  • brimonidine tartrate
  • Product-55394
  • CB-0301
  • IDP-118
  • JNJ-10229570-AAA
  • Product-10156
  • Product-49778

Valeant Pharmaceuticals International, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Valeant Pharmaceuticals International, Inc.:最近的開發平台趨勢

Valeant Pharmaceuticals International, Inc.:暫停中的計劃

Valeant Pharmaceuticals International, Inc.:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • ATON-004
    • CVTE-002
    • ezogabine
    • IDP-107
    • IDP-109
    • IDP-115
    • MC-5
    • pegaptanib sodium
    • RUS-350
    • taribavirin hydrochloride
    • tiazofurin
    • tramadol hydrochloride

Valeant Pharmaceuticals International, Inc.:企業發表

Valeant Pharmaceuticals International, Inc.:總公司和子公司的所地

Valeant Pharmaceuticals International, Inc.:主要製造設備

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08114CDB

Summary

Global Markets Direct's, 'Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016', provides an overview of the Valeant Pharmaceuticals International, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Valeant Pharmaceuticals International, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Valeant Pharmaceuticals International, Inc.
  • The report provides overview of Valeant Pharmaceuticals International, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Valeant Pharmaceuticals International, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Valeant Pharmaceuticals International, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Valeant Pharmaceuticals International, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Valeant Pharmaceuticals International, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Valeant Pharmaceuticals International, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Valeant Pharmaceuticals International, Inc. Snapshot
    • Valeant Pharmaceuticals International, Inc. Overview
    • Key Information
    • Key Facts
  • Valeant Pharmaceuticals International, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Valeant Pharmaceuticals International, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Valeant Pharmaceuticals International, Inc. - Pipeline Products Glance
    • Valeant Pharmaceuticals International, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Valeant Pharmaceuticals International, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Valeant Pharmaceuticals International, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Valeant Pharmaceuticals International, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Valeant Pharmaceuticals International, Inc. - Drug Profiles
    • brodalumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (halobetasol propionate + tazarotene)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • budesonide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-122
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • loteprednol etabonate next generation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rifaximin DR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BLO-020
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ezogabine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-125
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-126
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-127
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-128
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-129
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-130
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-131
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lapuleucel-T
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ribavirin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAL-021
      • Product Description
      • Mechanism of Action
      • R&D Progress
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPT-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • metyrosine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BLO-021
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-123
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-124
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VALBRO-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Valeant Pharmaceuticals International, Inc. - Pipeline Analysis
    • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Target
    • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Route of Administration
    • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Molecule Type
    • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action
  • Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates
  • Valeant Pharmaceuticals International, Inc. - Dormant Projects
  • Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ATON-004
      • (bupropion hydrochloride + selective serotonin reuptake inhibitor)
      • brodalumab
      • CVTE-002
      • ezogabine
      • IDP-107
      • IDP-109
      • IDP-115
      • MC-5
      • methylnaltrexone bromide
      • pegaptanib sodium
      • rifaximin
      • RUS-350
      • taribavirin hydrochloride
      • tiazofurin
      • UK-279276
  • Valeant Pharmaceuticals International, Inc. - Company Statement
  • Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Valeant Pharmaceuticals International, Inc., Key Information
  • Valeant Pharmaceuticals International, Inc., Key Facts
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Indication, 2016
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Stage of Development, 2016
  • Valeant Pharmaceuticals International, Inc. - Monotherapy Products in Pipeline, 2016
  • Valeant Pharmaceuticals International, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Valeant Pharmaceuticals International, Inc. - Partnered Products in Pipeline, 2016
  • Valeant Pharmaceuticals International, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Valeant Pharmaceuticals International, Inc. - Out-Licensed Products in Pipeline, 2016
  • Valeant Pharmaceuticals International, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Valeant Pharmaceuticals International, Inc. - Pre-Registration, 2016
  • Valeant Pharmaceuticals International, Inc. - Phase III, 2016
  • Valeant Pharmaceuticals International, Inc. - Phase II, 2016
  • Valeant Pharmaceuticals International, Inc. - Phase I, 2016
  • Valeant Pharmaceuticals International, Inc. - Preclinical, 2016
  • Valeant Pharmaceuticals International, Inc. - Unknown, 2016
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Target, 2016
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Route of Administration, 2016
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Molecule Type, 2016
  • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates, 2016
  • Valeant Pharmaceuticals International, Inc. - Dormant Developmental Projects,2016
  • Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products, 2016
  • Valeant Pharmaceuticals International, Inc., Other Locations
  • Valeant Pharmaceuticals International, Inc., Subsidiaries

List of Figures

  • Valeant Pharmaceuticals International, Inc. - Pipeline by Top 10 Indication, 2016
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Stage of Development, 2016
  • Valeant Pharmaceuticals International, Inc. - Monotherapy Products in Pipeline, 2016
  • Valeant Pharmaceuticals International, Inc. - Partnered Products in Pipeline, 2016
  • Valeant Pharmaceuticals International, Inc. - Out-Licensed Products in Pipeline, 2016
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Top 10 Target, 2016
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Route of Administration, 2016
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Molecule Type, 2016
  • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top